ArticleClinics (Sao Paulo, Brazil)2026
Combination of serum TBL1XR1, MFAP5, and PSA as diagnostic biomarkers for prostate cancer.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAdvanced prostate cancer (PCa) remains a leading cause of cancer-related mortality in men. While Prostate-Specific Antigen (PSA)-based early screening has demonstrated mortality reduction, its diagnostic accuracy remains limited. This study aimed to evaluate the potential of serum transducin (beta)-like-1 X-linked Receptor-1 (TBL1XR1) and Microfibrillar-Associated Protein-5 (MFAP5) as novel diagnostic biomarkers for supplementing PSA-based detection.
methodThrough bioinformatic analysis, TBL1XR1 and MFAP5 were identified as candidate markers, with their expression validated using reverse transcription-quantitative polymerase chain reaction. Diagnostic performance was assessed via Receiver Operating Characteristic (ROC) curve analysis, while Pearson correlation coefficients evaluated biomarker associations.
resultsSerum TBL1XR1 and MFAP5 levels were elevated in PCa patients, both exhibiting positive correlations with PSA concentrations. Individual AUC values reached 0.8197 (TBL1XR1) and 0.8139 (MFAP5). The free PSA (fPSA)/total PSA (tPSA) ratio showed decreased values in PCa cases, demonstrating superior diagnostic utility compared to total PSA alone. A combined panel of TBL1XR1, MFAP5, and PSA achieved an AUC of 0.939 with a Youden index of 0.756.
conclusionsTBL1XR1 and MFAP5 have the potential for PCa diagnosis. The synergistic application of TBL1XR1, MFAP5, and PSA significantly enhances diagnostic accuracy. These findings indicate that serum TBL1XR1 and MFAP5 represent promising diagnostic markers for PCa. The combination of serum TBL1XR1 and MFAP5 with PSA for diagnosis may potentially reduce unnecessary biopsies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.